SIETES :: 93212 citas

Resultados de la búsqueda por VALVULOPATÍA MITRAL REFINAR BÚSQUEDA

1.

Blotière P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, Rouget F, Zureik M, Coste J, Dray-Spira R. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019;93:. [Ref.ID 103248]

2.

Hylek EM. Dabigatran and mechanical heart valves - Not as easy as we hoped. N Engl J Med 2013;369:1264-6. [Ref.ID 96302]

3.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Stat C, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt J-U, Simoons ML, Van de Werf F, for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14. [Ref.ID 96301]

4.

Anónimo. Valvulopathies d'origine médicamenteuse. Prescrire 2013;33:668-72. [Ref.ID 96188]

5.

Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosenbraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9. [Ref.ID 93939]

6.

Montastruc F, Montastruc G, Vigreux P, Bruneval P, Guilbeau-Frugier C, Cron C, Bagheri H, Delisle B, Lapeyre-Mestre M, Pathak A, Montastruc J-L. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Br J Clin Pharmacol 2012;74:547-8. [Ref.ID 93709]

7.

Roth BL. Dopamine agonists and valvular heart disease. Dr. Roth replies. N Engl J Med 2007;356:1679-80. [Ref.ID 79842]

8.

Zanettini R, Pezzoli G. Dopamine agonists and valvular heart disease. Drs. Zanetini and Pezzoli reply. N Engl J Med 2007;356:1678-9. [Ref.ID 79841]

9.

Schade R, Andersohn F, Garbe E. Dopamine agonists and valvular heart disease. Dr. Schade and colleagues reply. N Engl J Med 2007;356:1678. [Ref.ID 79840]

10.

Sartiani L, Cerbai E, Mugelli A. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677-8. [Ref.ID 79839]

11.

Ziegler JL, Bukhman GY. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677. [Ref.ID 79838]

12.

Kast RE, Altschuler EL. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677. [Ref.ID 79837]

13.

Linkova H, Ruzicka E, Penicka M. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1676. [Ref.ID 79836]

14.

Stephens JW, Price DE, Ionescu A. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1676. [Ref.ID 79835]

15.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46. [Ref.ID 78773]

16.

Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. [Ref.ID 78772]

17.

Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9. [Ref.ID 78770]

18.

Grosset KA, Grosset DG. Pergolide in Parkinson's disease: time for a change?. Lancet 2004;363:1907-8. [Ref.ID 70295]

19.

Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83. [Ref.ID 69718]

20.

Anónimo. Methysergide. Cardiac valvulopathy, Australia. WHO Pharmaceuticals Newsletter 2001;1:10. [Ref.ID 56630]